november Aktiengesellschaft

EANS-News: november Aktiengesellschaft
PROGEN and Mitsubishi Chemical Europe GmbH Sign an Exclusive Distribution Contract for the PATHFAST® POCT Analyzing System

--------------------------------------------------------------------------------
  Corporate news transmitted by euro adhoc. The issuer/originator is solely
  responsible for the content of this announcement.
-------------------------------------------------------------------------------- 

New Products/Research & Development

Köln (euro adhoc) - Effective immediately, PROGEN Biotechnik GmbH, a subsidiary of november AG, exclusively distributes the PATHFAST® analyzing system of Mitsubishi Chemical Europe GmbH in Germany. The PATHFAST® analyzing system enables effective parallel processing of up to six patient samples or analytes in one run. High precision as well as a fast and easy-to-perform test procedure makes the PATHFAST® the ideal analyzing system on a cardiology, intensive care or an emergency ward, as an adequate 'outpost' of a central laboratory. The PATHFAST® analyzing system allows quantitative and reliable measurements from heparin or EDTA whole blood or plasma in emergency medicine (e.g. myocardial infarction, myocarditis). Available cardiac markers are Troponin I, CK-MB mass, Myoglobin, NT-proBNP as well as hsCRP.

Features of the PATHFAST® analyzing system: • meets the guideline of the German Cardiac Society (DKG, BNK) for a CV <10% at the 99% percentile for Troponin measurement • profile of cardiac markers (e.g. cTnI, CK-MB, NT-proBNP) in one test run • analysis from heparin or EDTA whole blood or plasma • simultaneous analysis of up to six samples or analytes • results in 17 minutes • integrated computer and printer, touch screen operation • barcode reader, RS-232C interface, LIMS connection, data transfer • no water connection and buffer system required • ready-to-use cartridge including all reagents and buffer • only one cartridge and one pipette tip per test run • no training required • attractive leasing offers

With the takeover of the distribution of the PATHFAST® analyzing system, november´s subsidiary PROGEN is expanding its product range in the area of emergency diagnostics. This high-quality analyzing system is an ideal supplement to PROGEN´s own product range which adds growth potential and supports PROGEN´s growth strategy and will contribute to increase sales turnovers.

About november AG/PROGEN Biotechnik GmbH november AG, Cologne, is an investment and holding company, listed in the prime standard of the regulated market of the German stock exchange (Deutsche Böse) with special focus on medical technology, biotechnology and environmental technology. november AG is 100% shareholder of PROGEN Biotechnik GmbH, Heidelberg. PROGEN is a DIN EN ISO 13485:2007 certified manufacturer of in vitro diagnostics (e.g. Borrelia, Hantavirus, FSME) and research reagents (e.g. antibodies, polypeptides, AAV, hyperphage) as well as specialist in the manufacturing of multiplex assays based on the Luminex® platform. PROGEN is member of the VDGH (German Association of Diagnostic Manufacturers).

About Mitsubishi Chemical Europe GmbH (PATHFAST®) Mitsubishi Chemical Europe GmbH and Mitsubishi Chemical Medience Corporation are a subsidiaries of Mitsubishi Chemical Corporation. The core business of Mitsubishi Chemical Medience comprises the development, production and distribution of analysis devices and reagents for fast and accurate emergency diagnosis.

end of announcement                               euro adhoc
-------------------------------------------------------------------------------- 

Contact:

Dr. Dirk Zurek
Tel.: +49 (0) 221 820 05 20 10
E-mail: ir@november.de

Branche: Biotechnology
ISIN: DE000A0Z24E9
WKN: A0Z24E
Index: CDAX, Prime All Share, Technology All Share
Börsen: Frankfurt / regulated dealing/prime standard
Berlin / free trade
Stuttgart / free trade
Düsseldorf / free trade
Hannover / free trade
München / free trade



Weitere Meldungen: november Aktiengesellschaft

Das könnte Sie auch interessieren: